Today's top medical abstracts
Oncology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?

Home
General Oncology
For Practicing
Oncologists
Conferences
Jobs
Newsletters
My Library
Topics in
Oncology
        Alternative Therapies
        Anemia/Polycythemia
        BMT/SCT
        Basic Science/Genetics
        Bone/Cartilage
        Breast
        Carcinogenesis
        Coagulation/Bleeding Dz
        Colorectal Cancer/Polyps
        Dermatologic Oncology
        Diagnostics/Radiology
        Economics of Medicine
        Endocrine Oncology
        GI Oncology
        Gynecologic Oncology
        Head and Neck
        Hepatobiliary/Pancreas
        Leukemia/Lymphoma
        Lung/Thoracic Oncology
        Myeloproliferative Dz
        Neurologic Oncology
        Pain/Palliative Care
        Pediatric Heme/Oncology
        Pharmacology/Therapy
        Popular Press
        Renal/Urologic
        Side Effects
        Soft Tissue/Sarcoma
        Transfusion Medicine
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
 
Sponsor
For Practicing Oncologists
Improving Your Bottom Line: Mid Year Analysis Vital to Practice
Owen Dahl, Owen Dahl Consulting
FDA Update: Immune Response Robustness Correlates with Survival in Brain Cancer Vaccine Trial
Tracy Hampton, PhD, MDLinx Oncology
  See all
Mucosal Adenocarcinoma in Barrett's Oesophagus Article Summary

Print     Email This Article     Save in My Library   Free Abstract
Pech O et al. – Endoscopic therapy was highly effective and safe, with an excellent long-term survival rate. Risk factors identified may help stratify patients who are at risk for recurrence and those requiring more intensified follow-up.

Methods
  • Data analysis at 5y from a prospective cohort study at an academic tertiary care center (1996 to 2002)
  • 61 pts with HGIN and 288 with BC (173 short-segment; 176 long-segment Barrett’s) from a total of 486 patients presenting with Barrett’s neoplasia; submucosal or more advanced cancers were excluded

Results
  • Endoscopic resection was performed in 279 pts, photodynamic therapy in 55, and both procedures in 13; 2 pts received argon plasma coagulation
  • The mean follow-up period was 63.6 ± 23.1 mos
  • CR was achieved in 337 pts (96.6%); surgery was necessary in 13 (3.7%) after endoscopic therapy failed
  • Metachronous lesions developed during the follow-up in 74 pts (21.5%); 56 died of concomitant disease, but none died of BC
  • 5y survival rate was 84%
  • The risk factors most frequently associated with recurrence were piecemeal resection, long-segment Barrett's, no ablative therapy of Barrett's esophagus after CR, time until CR achieved >10 mos and multifocal neoplasia

 

Sponsor
--- GI ONCOLOGY TOP ARTICLES ---

Receive free subspecialty "5-minute updates" via email



Sponsor
Read a Different Specialty
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology
Profession Index
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
Sponsor
Sponsor
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2008 MDLinx, Inc.